Test

*Note: Mol2Net conference is associated to different MDPI journals special issues guest edited by Mol2Net Conference Committee members. This is an strategy to increase the online post-publication visibility of papers and conference, promote post-publication brainstorming discussion, and increase authors feedback. This association implies that our conference perform post-publication indexing of selected papers already published in MDPI journals with the consent of the issue editors. We publish free-of-cost these post-publication summaries. They include a shortened title, corresponding author info, and paper cover pdf file. The cover pdf file contains paper first page with all authors, abstract, full reference , and link to original papers.

Reference: This is a post-publication summary note for the paper published in the special issue Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering, Edited by: Dr. I.A. Neacsu and Dr. B.S. Vasile, Managing Editor: C. Zha, Visit the link to see original paper. Reference: Pharmaceutics 2022, 14(4), 858; https://doi.org/10.3390/pharmaceutics14040858

Summary: Specific targeting, selective stimuli-responsiveness, and controlled release of anticancer agents are requested for high therapeutic efficiency with a minimal adverse effect. Herein, we report the sophisticated synthesis and functionalization of fluorescent mesoporous silicon (FMPSi) nanoparticles decorated with graphene oxide (GO) nanosheets. GO-wrapped FMPSi (FMPSi@GO) was loaded with a cisplatin (Cis) anticancer agent, and Cis-loaded FMPSi@GO (FMPSi-Cis@GO) exhibited the dual stimuli (pH and NIR)-responsiveness of controlled drug release, i.e., the drug release rate was distinctly enhanced at acidic pH 5.5 than at neutral pH 7.0 and further enhanced under NIR irradiation at acidic pH condition. Notably, dequalinium-conjugated FMPSi-Cis@GO (FMPSi-Cis@GO@DQA) demonstrated an excellent specificity for mitochondrial targeting in cancer cells without noticeable toxicity to normal human cells. Our novel silicon nanocarriers demonstrated not only stimuli (pH and NIR)-responsive controlled drug release, but also selective accumulation in the mitochondria of cancer cells and destroying them.